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Phenotypic diversity arises in tumors just as it does in
developing organisms, and tumor recurrence fre-
quently manifests from the selective survival of diver-
gent drug-resistant cells. Although the expanding tumor
cell populationmay be successfully targeted, drug-resis-
tant cells may persist and sustain the tumor or enter
dormancy before igniting a future relapse. Herein, we
show that partial knockdown of nucleoporin p62
(NUP62) by small-interfering RNA confers cisplatin re-
sistance to cultured high-grade ovarian carcinoma cells.
TreatmentwithNUP62 small-interferingRNAandcisplatin
leaves resistant cells in a state of dormancy; somedormant
cells can be induced to proliferate by transient induction
of NUP62 expression from an ectopic expression con-
struct. In addition to suggesting functional links between
nuclear pore complex architecture and cancer cell sur-
vival, the culture system provides a novel experimental
window into the dynamics of tumor cell drug resistance
and dormancy. (Am J Pathol 2012, 180:375–389; DOI:
10.1016/j.ajpath.2011.09.024)
Ovarian cancer is the fifth leading cause of cancer-related
deaths among US women; among gynecological tumors, it
most frequently results in death.1 The prevailing treatment
for ovarian cancer is surgical debulking, followed by plati-
num-based chemotherapy. Although ovarian carcinomas
initially respond well to treatment with platinum salts, such
as cisplatin, most recur, a course that is also followed by
other tumor types. Modulation of drug uptake and efflux,
enhanced mechanisms of detoxification, inhibition of apop-
tosis, and recovery or enhancement of DNA repair mecha-
nisms2 have been associated with enhanced survival of
tumor cells challenged with platinum salts. Although the
mechanisms of tumor cell escape from cisplatin are not wellunderstood, alterations in genes or gene products with di-
verse functions may influence sensitivity to platinum salts,
including metallothionein (an intracellular metal sink3),
CCND1 (a G1 cyclin
4), ERCC1 (an enzyme involved in DNA
excision repair5,6), glutathione S-transferase (thought to
modulate signal transduction kinase cascades in response
to stress7), IL-6 (a cytokine8), and type IV collagen.9 In
certain cultured ovarian carcinoma cells, modulators of
apoptosis, including p53,10–12 X-linked inhibitor of apopto-
sis protein,13,14 and Akt,15,16 work as interdependent deter-
minants in the response to platinum salts.17 Rather than
being determinants of response to therapeutic challenge,
however, p53 mutations appear almost ubiquitously and
appear to function as early or driver mutations in high-grade
ovarian carcinomas.18,19
The recurrence of tumors from remnant tumor cells pres-
ents an important challenge to the success of cancer che-
motherapy. Adding to the complexity of this challenge, drug
resistance of remnant tumor cells can be conferred by
ephemeral epigenetic variability that is obscured on recur-
rence of the tumor. A review20 of retreatment of relapsed
tumors of different types revealed that transient resistance
to chemotherapy is common, and the authors statistically
discounted somatic mutation as the prevailing mechanism,
suggesting instead epigenetic modalities. A study21 of re-
treatment of patients with ovarian cancer with platinum
drugs after remission and relapse with the same regimen of
chemotherapy revealed surprisingly high probabilities of
success. Analogously, in some animal models, growth of
remnant cells does not result in the appearance of resistant
tumors; rather, it results in the growth of tumors that, when
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similarly to the untreated tumor.2,22 Recent studies23 of tu-
mor cells in culture have shown that populations of drug-
tolerant cells persist after treatment with different chemo-
therapeutic agents and that these cells are mostly
quiescent and express surface markers in common with
cancer stem cells. When these cells remain in culture in the
presence of drug, a fraction produce colonies of cells with
relatively stable tolerance; that cell population remains tol-
erant in the presence of drug and for many generations after
drug removal. The frequency with which tolerant and stably
tolerant cells appeared in these experiments also suggests
mechanisms that do not involve genetic mutations. Further
studies23 indicated that chemical agents that inhibit histone
demethylation also block acquisition of drug tolerance, sug-
gesting an epigenetic mechanism.
The functions of the nuclear pore complex (NPC) in nu-
cleocytoplasmic transport and chromatin organization
make it a potential nexus for control of normal and cancer
cell phenotypes. The NPC assembles in a modular form
from multiples of eight nucleoporin (NUP) subcomplexes
(as visualized24 and modeled25), with a central framework
consisting of a symmetric pair of central inner rings (con-
taining NUP107-160 subcomplexes26). Asymmetric annular
rings line the cytoplasmic (containing the NUP88-NUP214
subcomplex27,28) and nuclear (containing NUP15329) faces
of the pore, whereas asymmetric filamentous structures
project from the annular rings into the nucleus (containing
NUP153-Tpr29) or cytoplasm (containing NUP35830). The
NUP62 subcomplex, which contains the FG-repeat
NUP62,31 forms two rings on the inner channel of the
pore.32,33 Although the major framework components of the
NPC are generally static and rigid, the FG-repeat–contain-
ing NUPs, which include NUP62, NUP98, NUP153, and
NUP358, mediate transport of cargo and karyopherins by
interacting dynamically with the NPC and exploiting their
own structural plasticity.34 A subset of the FG-repeat–con-
taining NUPs (including NUP62) function in transcriptional
regulation at intranuclear sites distal to the NPC.35,36 Inter-
actions with FG-repeat and possibly other NUPs appear to
play a role in chromatin organization at the nuclear enve-
lope or within the nucleus.36,37
We have observed that knockdown of NUP62 results in
growth retardation of several cell lines, including cells de-
rived from a high-grade ovarian carcinoma (TOV112D) that
we chose to study further. The TOV112D cell line was gen-
erated before chemotherapy or radiation therapy from a
tumor displaying endometrioid histological features and an
extremely aggressive disease course.38 Correspondingly,
the cells are rapid growing and display a high frequency of
colony formation in semisoft medium and of tumor formation
in nude mice.38 Recent studies39–41 have shown that p53
mutations are present in most high-grade ovarian carcino-
mas with either serous or endometrioid histological charac-
teristics; consistent with other tumors of the same lineage,
TOV112D cells possess a mutant p53 genotype.38 We will
show that knockdown of NUP62 pauses cells upstream of
the G1-S–phase border and confers resistance to cispla-
tin through a mechanism that appears to require enrich-
ment of NPCs lacking NUP62. This contrasts with other
agents that pause progression in the G1 or G2 phase ofthe cell cycle and enhance sensitivity to the cytotoxic
effects of cisplatin.42–48 Knockdown of NUP62 in the
presence of cisplatin leaves surviving cells in a state
resembling cellular dormancy,49 and spontaneous colo-
nial proliferation of the apparently dormant cells was ob-
served only rarely in long-term cultures. In contrast, tran-
sient induction of NUP62 expression pushed resistant
cells out of dormancy, resulting in rapid colonial expan-
sion. The modulation of nuclear pore architecture repre-
sents a novel mechanism through which tumor cells
could acquire transient resistance to certain chemother-
apeutic agents, and the culture system represents a dy-
namic and controlled experimental tool for studying entry
into and emergence from cancer cellular dormancy.
Materials and Methods
Cell Lines
The human ovarian carcinoma cell line TOV112D was
obtained from American Type Culture Collection (Manas-
sas, VA). Cultures were maintained in Dulbecco’s modi-
fied Eagle’s medium (Cellgro, Manassas, VA) supple-
mented with 10% to 15% fetal bovine serum (tetracycline
free for TOV112D-CAP cells).
Antibodies
Antibodies to NUP62 (sc-25523; Figure 1), C23 (nucleo-
lin, sc-8031), cyclin E (sc-198), and cyclin A (sc-751)
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibody to NUP160 (A301-790A) was obtained
from Bethyl Laboratories (Montgomery, TX). Antibody to
NUP133 (H00055746-M01) was obtained from Abnova
(Walnut, CA). Monoclonal antibody (MAB) 414 (MMS-120R)
was obtained from Covance (Princeton, NJ). Antibody to
NUP62 conjugated to fluorescein isothiocyanate (611962)
was obtained from BD Biosciences (San Jose, CA). Phos-
phorylated histone H3 (Ser10) antibody (06-570) was ob-
tained from Upstate Biotechnology (Millipore, Billerica, MA).
Antibody to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH; MAB374) was obtained from Chemicon (Milli-
pore). All secondary antibodies for immunofluorescencemi-
croscopy were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA).
Immunofluorescence Microscopy
Subconfluent cells were cultured on glass coverslips.
Immunofluorescence staining was performed similarly to
that performed by Maeshima et al.50 Cells were fixed with
3.7% paraformaldehyde in PBS and quenched with 50
mmol/L glycine in HMK buffer (20 mmol/L HEPES, pH 7.5;
1 mmol/L MgCl2; and 100 mmol/L KCl). Coverslips were
briefly washed with HMK. After cells were treated with
0.5% Triton X-100 in HMK, they were treated with block-
ing solution (10% normal donkey serum and 1% bovine
serum albumin in HMK buffer). Cells were incubated with
primary antibody for 1 to 2 hours at room temperature or
overnight at 4°C. After washing with HMK five times, the
tical sec
esulted
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ImmunoResearch). Cells were washed in PBS and
mounted with VectaShield mounting medium with DAPI
(Vector Laboratories, Burlingame, CA). Bright-field mi-
croscopy was performed using a Zeiss Axioplan 2 micro-
scope (Carl Zeiss Microscopy, LLC, Thornwood, NY).
Images were acquired with either 40 (air) or 63 (oil)
objectives in Z-stack series extending 10 to 15 m.
Bright-field images were compiled after three-dimen-
sional deconvolution (AutoQuant; MediaCybernetics, Be-
thesda, MD) and projection.
Western Blot Analyses
Cell lysates were prepared by washing adherent cells once
in PBS, followed directly by lysis in SDS sample buffer (62.5
mmol/L Tris-HCl, pH 6.8; 10% glycerol; 2% SDS; 5% -mer-
captoethanol; and 125 g/mL bromophenol blue). SDS-
Figure 1. Knockdown of NUP62 reduces NUP62 immunolabeling but does not
siRNA treatment of TOV112D cells. Dilutions of control siRNA sample (lanes 1
Immunofluorescence microscopy of NUP62 and NUP133 in control and NUP6
250-nm intervals and merged, and images projected from three planes (x,y; x,z;
TOV112D-9 cells treated with control, NUP62, NUP133, or NUP160 siRNA. Op
cytoplasmic annulate lamellae in cells treated with NUP133 or NUP160 siRNA rPAGE and transfers of proteins to nitrocellulosemembraneswere performed as described by the Amersham ECL Plex
Western blotting system (GE Healthcare, Pittsburgh, PA).
Membranes were scanned by the Typhoon Trio (GE Health-
care) and analyzed with ImageQuant TL (GE Healthcare) or
developed using the Amersham ECL Western blotting sys-
tem (GE Healthcare).
Assembly and Transfection of Tetracycline-
Inducible NUP62 Expression Constructs
A 1569-bp NheI/HindIII fragment containing the human
NUP62 cDNA (cDNA clone MGC: 119675; IMAGE:
40011537; the full-length human NUP62 protein) was
cloned into the NheI/HindIII site of pTRE-Tight-BI-DsRed2
DNA vector (Clontech, Mountain View, CA) to make
pTRE-Tight-BI-DsRed2-NUP62. Construct integrity was
confirmed by DNA sequence analysis. Cells were plated
at 70% to 80% confluency 24 hours before transfection.
PCs. A:Western blot analyses of NUP62, NUP133, and NUP160 knockdown by
rrelate the reductions in signal intensity with fraction of protein reduction. B:
treated TOV112D-9 cells. Optical sections (63, oil immersion) were taken at
are shown. Scale bar  5 m. C: MAB414 immunofluorescence microscopy of
tions (40, air) were taken at 500-nm intervals and merged. Accumulation of
after NPC disruption. Scale bar  10 m.ablate N
to 3) co
2 siRNA-
and z,y)Transfections were performed by the calcium phosphate
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TOV112D-9 was derived from TOV112D by stable trans-
fection with pTet-On (Tet-On Gene Expression Systems;
Clontech). The Ase I-linearized pTRE-Tight-BI-DsRed2-
NUP62 was stably transfected into TOV112D-9 cells by
cotransfection with pIND/Hygro and selection with 200
g/mL Hygromycin B to generate TOV112D-CAP cells.
Selected clones were cultured in tetracycline-free fetal
bovine serum and induced to express NUP62 with 2 to 4
g/mL doxycycline hyclate. Regulated expression was
verified by immunoblot analysis.
Knockdown by siRNA Transfection
Cells were plated at 3  104/cm2 using 10% fetal bovine
serum in Dulbecco’s modified Eagle’s medium without the
addition of antibiotics for 24 hours. Cells were transfected
with small-interfering RNA (siRNA) using Lipofectamine
RNAiMAX (Invitrogen, Carlsbad, CA) and the manufactur-
er’s recommended procedure. The siRNAs for NUP62 (sc-
36107), NUP133 (sc-60035), NUP160 (sc-106318), control
siRNA-A (sc-37007), and control siRNA-B (sc-44230) were
obtained from Santa Cruz Biotechnology.
Cisplatin Resistance and Survival Assays
Subconfluent cells were transfected with control or NUP
siRNAs and incubated for 24 hours. Cisplatin (EMD4
Biosciences, Darmstadt, Germany) was then added at a
different concentrations to some cultures for 48 hours in
the continuing presence of the siRNAs. Live cells were
identified by Trypan blue exclusion and counted.
TOV112D-9 or TOV112D-CAP cells were plated at 30 
104 cells per well on six-well plates in 10% tetracycline-
free fetal bovine serum in Dulbecco’s modified Eagle’s
medium without antibiotics. The cells were treated with 2
to 4 g/mL doxycycline to induce expression of NUP62.
Cell Cycle Analyses
For fluorescence-activated cell sorter (FACS) analyses,
cells were harvested after trypsin treatment and trypsin
inactivation in serum-containing medium. Harvested cells
were rinsed with PBS once, resuspended in PBS contain-
ing 5 mmol/L EDTA, fixed in ice-cold 70% ethanol by the
addition of absolute ethanol dropwise while lightly vortex
mixing, and incubated for at least 30 minutes at 4°C.
Fixed cells were rinsed in 5 mmol/L EDTA in PBS twice to
remove ethanol and resuspended in 5 mmol/L EDTA and
1% bovine serum albumin in PBS. Cells were treated with
RNase A (Sigma-Aldrich, St. Louis, MO) and 0.1% Nonidet
P-40 in PBS for 1 hour and stained with propidium iodide
solution (Sigma-Aldrich). An FACScan fitted with CellQuest
software and a BD LSR II laser with Diva software (BD
Biosciences) were used for analytical flow cytometry. For
cell sorting, cells were stained with Vybrant DyeCycle
Green stain (V35004 from Invitrogen) and processed with
the MoFlo sorter (Beckman Coulter, Inc., Indianpolis, IN).
Cell cycle arrest was achieved by 24-hour incubation
of subconfluent cells with 2 g/mL aphidicolin. Cells were
rinsed with medium once and released in fresh mediumlacking aphidicolin (0 hour), and time points were taken
hourly. Cell cycle progression was verified by FACS anal-
ysis. Cell lysates were analyzed by using Western blot
analysis. Total protein loading was standardized by Coo-
massie blue staining analysis of samples. Signal intensi-
ties were determined by densitometry and normalized to
GAPDH or nucleolin, as indicated.
Electron Microscopy and Quantification of Pore
Diameters
Tissue samples were immediately fixed in buffered formalin on
removal in the operating room and routinely processed. Ultra-
thin sections were mounted on grids. Sections were viewed
using a Jeol (Peabody, MA) 1200 EX electron microscope
equipped with an Advanced Microscopy Techniques
(Wobum, MA) digital camera. Electron micrographs were
taken at 50,000 and imported into an image morphometry
system (Neurolucida; MicroBrightField, Inc., Williston, VT) for
making and obtaining measurements at a print magnification
of209,000. Pore external diameters, defined by marginated
heterochromatin, and internal diametersweredigitally imaged.
A total of 423 pores were measured.
Immunohistochemical Data
Formalin-fixed, paraffin-embedded sections were cut (5
m thick) and attached to slides. Removal of paraffin,
rehydration, and treatment with hydrogen peroxide were
performed as previously described.51 Antigen retrieval
was performed by treated sections with 10 mmol/L citrate
buffer (pH 6.0) for 4 minutes at 125oC in a pressure
cooker. After cooling, slides were rinsed with PBS. Sec-
tions were incubated for 2 hours at 22oC with primary
antibody diluted in PBS containing 1% bovine serum
albumin and 5% goat serum. The Ultravision LP Detec-
tion System was used as a second antibody and for
development, according to the manufacturer’s specifi-
cations (Thermo Fisher Scientific, Waltham, MA). Tu-
mor samples were obtained from archival materials of
the Department of Pathology, Mount Sinai School of
Medicine (New York, NY), that have been collected
with Institutional Review Board approval, as applica-
ble. All fresh tumor samples were de-identified before
analysis; hence, the studies using these samples are
not considered human subject research by the U.S.
Department of Health and Human Services.
Colony Staining
Colonies were rinsed with PBS, then fixed at 20o for 5
minutes with paraformaldehyde (3.7% formalin, 70% eth-
anol, and 5% acetic acid, brought to volume with normal
saline). Colonies were then rehydrated with several
changes of water and stained with 0.15% crystal violet.
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Partial Knockdown of NUP62 Alters NPC
Composition
We first asked whether siRNA-mediated knockdown of
NUP62 overtly alters the abundance of NPCs in the nuclear
envelope of TOV112D cells. The TOV112D cell line was
modified to express the tetracycline transcriptional activator
by DNA-mediated transfection of pTet-On, an expression
construct for the positive tetracycline transactivator protein
(Clontech) to generate TOV112D-9 cells. Several prelimi-
nary titration experiments were performed to establish ap-
propriate conditions for siRNA-mediated knockdown of
NUP62, NUP133, and NUP160. Conditions were selected
that result in 75% to 90% reductions in the total cellular
accumulation of the NUPs without affecting accumulation of
GAPDH (Figure 1A). Knockdown of NUP62 under these
conditions resulted in reduction of NUP62 immunolabeling
in NPCs on the nuclear envelope and among cytoplasmic
annulate lamellae, whereas double-immunolabeling exper-
iments revealed that the abundance or distribution of
NUP133 (a component of the inner core of the NPC) was not
altered (Figure 1B). The absence of changes in the immu-
nolabeling pattern of NUP133 suggests that removal of
NUP62 does not disrupt nuclear pores or overtly alter their
distribution. The images shown in Figure 1, B and C, are
projections of merged optical sections rather than a
single section, and reveal NUP signals derived from
NPCs on planes through the entire nucleus, including
the equatorial ring (observed when viewing a single
central section of the nucleus) and the dorsal/ventral
surfaces (Figure 1B; x,y; x,z; z,y).
Knockdown of either of two inner ring complex proteins
(NUP107 or NUP133) has removed NPCs from the nuclear
envelope, accompanied by down-regulation of some inner
complex proteins and accumulation of other NUPs in the
cytoplasm as annulate lamellae.52–54 Similarly, we show
that, using the conditions used herein, knockdown of
NUP133 and of another inner ring complex protein,
NUP160, denudes the nuclear envelope of NPCs, accom-
panied by accumulation of FG-repeat–containing NUPs
(detected by the FG-repeat–directed antibody, MAB41455)
in cytoplasmic annulate lamellae (Figure 1C). Knockdown
of NUP160 will be used to disrupt NPCs in experiments
described later. In contrast to NUP133 and NUP160, knock-
down of NUP62 under the same conditions did not disrupt
NPCs, although a weaker signal was observed in some
cells because NUP62 (an FG-repeat protein) is one of the
antigenic targets of MAB414 (Figure 1C). Together, the data
suggest that partial knockdown of NUP62 does not disrupt
NPCs or cause cytoplasmic dispersal of FG-repeat pro-
teins; rather, it results in accumulation of NUP62-depleted
NPCs.
NUP62 Protein Accumulation Displays a Peak in
the Early G1 Phase of the Cell Cycle
Cultures of TOV112D-9 cells were blocked at the late
G1-S phase of the cell cycle by aphidicolin, then re-leased. At 1-hour intervals after release, cells were ana-
lyzed for DNA content by FACS analysis and for expres-
sion of NUP62, cyclin A, cyclin E, phosphorylated histone
H3 (phosphoserine 10), nucleolin, and GAPDH by using
Western blot analysis. As shown by FACS analysis of
DNA content, TOV112D-9 cells are paused in late G1-S
by aphidicolin (Figure 2A, 0 hour); after aphidicolin is
removed, the cells rapidly enter the S phase (Figure 2A,
3 hours) and proceed to G2 (Figure 2A, 9 hours), then
proceed through the G2 and M phases to return to G1
(Figure 2A, 18 hours). Intense phosphorylation of histone
H3 at serine 10 indicates cells proceeding through the
late G2 and M phases of the cell cycle.
56 In somatic cells,
up-regulation of cyclin A is observed during the S phase,
whereas cyclin E expression peaks during progression
through G1 and the G1-S boundary, and is attenuated
during the S phase.57 Consistent with the FACS analysis,
a peak of cyclin A expression was observed between 2
and 9 hours (S phase), a peak of phosphorylated histone
H3 was observed between 9 and 14 hours (G2-M), and
two peaks of cyclin E expression were observed (0 to 2
and 18 to 20 hours for G1–early S and approaching
mid-G1, respectively). The expression of NUP62 (re-
ported as the 62-kDa band bound by MAB414) was ob-
served to peak in the early G1 phase of the cell cycle (16
to 19 hours), accompanying the decline in phophorylated
histone H3 and preceding the second peak of cyclin E
expression (Figure 2B). The expression of NUP62 was
normalized against GAPDH (cytoplasmic protein) and
nucleolin (nuclear protein). In both cases, a peak in
NUP62 accumulation was observed in the early G1 phase
of the cell cycle (Figure 2C).
Equivalent total protein samples from whole cell ly-
sates made 3, 8.5, and 17.5 hours after release from
aphidicolin block were analyzed by using Western blot
analysis for NUP62 accumulation. Because levels of pro-
tein accumulation do not vary linearly with band intensi-
ties in Western blot analyses, these samples were pro-
cessed on the same blot as a series of whole cell lysate
dilutions (Figure 2D). By comparison to the dilution se-
ries, the NUP62 amounts accumulated in 3- and 17.5-
hour samples appear to differ by approximately twofold.
Proliferating TOV112D-9 cells were also stained for DNA
content with membrane-permeable Vibrant DyeCycle
Green (Invitrogen); sorted by DNA content into G1, S, and
G2-M populations; and loaded at equal cell numbers per
lane for Western blot analysis (Figure 2D). In this analysis,
increased accumulation of NUP62 is observed in the
G2-M population. In this type of analysis, the transient
peak of NUP62 accumulation in early G1 is averaged into
the signal from the whole G1 population. The larger total
nuclear mass of cells in the G2-M phase also could con-
tribute to the enhanced NUP62 signal observed in cells at
that phase, particularly when loading according to total
cell number. FACS analyses of DNA content and NUP62
immunofluorescence revealed peaks of NUP62 signal in
fractions of cells in the G1 and G2-M phases. Together,
these observations suggest the possibility that enhanced
accumulation of NUP62 may begin before the completion
of abscission during late cytokinesis and may extend into
the early G1 phase. This interpretation also would be
380 Kinoshita et al
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accumulation commences as phosphorylation of histone
H3 is declining.
Modulation of NUP62 Levels Is Required for
Progression through the G1 Phase of the Cell Cycle
The siRNAs were used to partially knock down NUP62
expression in TOV112D-9 cells, as previously described.
Subconfluent TOV112D-9 cells were treated with NUP62
and control siRNAs, then analyzed for DNA content and
cell cycle distribution by FACS analysis. Partial knock-
down of NUP62 by siRNA resulted in accumulation of
cells in the G1 compartment of the cell cycle (Figure 3A).
Removal of NUP62 siRNA from arrested cultures results
in the gradual recovery of the nominal growth rate over a
few days. The TOV112D-9 cells were further engineered
by DNA-mediated transfection of a construct containing a
tetracycline activator-induced promoter (TRE) driving ex-pression of human NUP62 cDNA (pTRE-Tight-BI-
DsRed2-NUP62, derived from pTRE-Tight-BI-DsRed2;
Clontech). The selected cell line (TOV112D-CAP) over-
expresses NUP62 when doxycycline is added to the me-
dium (Figure 3B). The TOV112D-CAP cells were used to
analyze the effects of forced NUP62 overexpression on
cell cycle distribution. Although a reduction in the rate of
cell accumulation was observed in the doxycycline-in-
duced cultures, a comparison of the FACS profiles of
cultures with and without doxycycline did not reveal
growth arrest in a specific phase of the cell cycle. Rather,
the accumulation of signal in the2N compartment of the
induced cultures indicated that overexpression of NUP62
resulted in reduction of the G1 phase peak and induction
of apoptosis in some cells (Figure 3C). Together, the data
provide evidence that both up- and down-modulations of
NUP62 accumulation, and its putative impact on the ar-
chitecture of NPC populations, are required for success-
Figure 2. NUP62 accumulation in TOV112D
cells peaks in the early G1 phase of the cell
cycle. A: FACS analysis of TOV112D-9 cells after
release from aphidicolin block. DNA was stained
quantitatively with propidium iodide. AS, asyn-
chronously growing culture; 0 hours (h), culture
immediately before release; 3 h, culture 3 hours
after release; 9 h, culture 9 hours after release;
18 h, culture 18 hours after release. B: Western
blot analysis of cyclins A and E, phosphorylated
histone H3 (Phospho-H3), NUP62 (using
MAB414), nucleolin, and GAPDH in whole cell
lysates of TOV112D-9 cells at selected times after
release from aphidicolin block. C: Densitometry
analyses of NUP62 signals normalized to nucleo-
lin or GAPDH. Mean values from three experi-
ments were normalized to reflect the same com-
bined signal for all points; means for each point
are shown with SDs. D: Left top panel: Whole
cell lysates were generated at the indicated time
points after aphidicolin block, loaded at equiv-
alent total protein, and analyzed by using West-
ern blot analysis for NUP62 and Phospho-H3. A
series of dilutions of TOV112D-9 cell whole cell
lysates analyzed on the same Western blot with
NUP62 antibody is shown for comparison. Left
bottom panel: Proliferating TOV112D-9 cells
were sorted using Vibrant DyeCycle Green stain
(Invitrogen) into G1, S, and G2-M phases (T re-
fers to the total population), and whole cell ly-
sates derived from 0.5  105 or 1  105 cells (as
indicated) were loaded per lane for Western blot
analysis with NUP62 antibody. Right panel:
FACS analyses of proliferating TOV112D-9 cells,
showing DNA content (propidium iodide stain)
versus cell count (DNA/Cell Counts), DNA con-
tent versus NUP62 immunofluorescence (DNA/
NUP62), and DNA content versus background
fluorescence (DNA/Control).ful transit across the G1 phase.
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by knockdown of NUP62 was further resolved. The
TOV112D-9 cells were blocked in the late G1-S phase by
incubation with aphidicolin for 24 hours, and then incu-
bated with NUP62 siRNA and aphidicolin for a further 24
hours. At 48 hours, the cells were cultured in medium
containing only NUP62 siRNA. After removal of theaphidicolin block, virtually all of the cells progressed
through the S and M phases, even in the continuing
presence of NUP62 siRNA (Figure 4A). This result indi-
cates that down-regulation of NUP62 blocks cell cycle
progression through an earlier period in the G1 phase,
upstream of the aphidicolin block at late G1-S. To support
this conclusion, cells were incubated with NUP62 siRNA
Figure 3. Modulation of NUP62 levels is re-
quired for progression through the G1 phase in
TOV112D cells. A: FACS analysis of TOV112D-9
cells treated with control or NUP62 siRNA. DNA
was stained quantitatively with propidium io-
dide. Data on the right indicate percentage of
cells (mean values) in each gated phase. B: Left
panel: Western blot analysis of NUP62 expres-
sion in TOV112D-CAP cells. Cultures of
TOV112D-CAP cells lacking doxycycline [Dox(-
)], supplemented with doxycycline for 48 hours
[Dox()], or lacking doxycycline and treated
with control, NUP62, or NUP160 siRNA. Right
panel: Western blot signals were quantified,
and NUP62 signal was normalized, against sig-
nals for GAPDH or nucleolin. C: FACS analyses
of TOV112D-CAP cells cultured in the presence
[Dox()] or absence [Dox(-)] of doxycycline.
DNA was stained quantitatively with propidium
iodide. Data on the right indicate percentage of
cells (mean values) in each gated phase.
Figure 4. Knockdown of NUP62 specifically re-
stricts progression through the G1 phase up-
stream of the G1-S transition. A: Cells released
from aphidicolin block proceed through the cell
cycle in the presence of NUP62 siRNA. The se-
quence of events is traced in the top diagram:
Cells were incubated with aphidicolin 48 hours
(h) before release; 24 h before release, NUP62
siRNA was added; at 0 h, cells were released
from aphidicolin block but continued in the
presence NUP62 siRNA. FACS analysis results of
propidium iodide binding at 0 hours and the
times indicated after release are shown. B: Many
cells treated with NUP62 siRNA are restricted
from progressing to an aphidicolin block. The
sequence of events is traced in the top diagram:
Cells were incubated with NUP62 at 48 h before
release; 24 h before release, aphidicolin was
added; at 0 h, cells were released from aphidi-
colin block but remained in the presence NUP62
siRNA. FACS analyses of propidium iodide bind-
ing at 0 hours and the times indicated after re-
lease are shown.
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a further 24 hours. At 48 hours, the cells were changed to
medium containing only NUP62 siRNA. In this experi-
ment, a peak of cells remained blocked in G1 by down-
regulation of NUP62, even after the removal of aphidicolin
(Figure 4B), suggesting that the NUP62 siRNA block pre-
cedes that of aphidicolin. However, a small, discrete pop-
ulation of cells also was observed to enter the S phase
after removal of aphidicolin. Because NUP62 siRNA
knocks down NUP62 accumulation only partially, the
block to cell cycle progression is not absolute and most
likely behaves similarly to a weir. Although the rate of
accumulation is reduced, a few cells accumulate suffi-
cient NUP62 to spill over the weir, only to be blocked at
the G1-S boundary by aphidicolin. When aphidicolin is
removed, this discrete group of cells progresses syn-
chronously through the S phase as is evident 4 hours
after release (Figure 4B).
Partial Knockdown of NUP62 Confers
Resistance to Cisplatin
Because some agents that pause cell cycle progression
enhance sensitivity to cisplatin, we queried whether par-
tial knockdown of NUP62 affects the cytotoxic response
of cultured ovarian carcinoma cells to cisplatin treatment.
The TOV112D-9 cell line was grown in the presence of
NUP62 or control siRNA for 24 hours (to 60% to 80%
confluence), then treated with different concentrations of
cisplatin for 48 hours (continuing in the presence of
NUP62 siRNA). In contrast to the reported effects of other
inhibitors of cell cycle progression, siRNA-mediated
knockdown of NUP62 enhanced survival of cells treated
with cisplatin and conferred resistance to higher concen-
trations of the drug (Figure 5A). The data shown were
collected at 48 hours after adding cisplatin; although the
survival of cells remaining after treatment with 4 g/mL
cisplatin for 48 hours was greatly enhanced by treatment
with NUP62 siRNA, the remaining cells entered a period of
protracted growth arrest and continued to die off slowly,
even after cisplatin was removed (described later). Further
experiments revealed that protection against cisplatin cyto-
toxicity is conferred by the generation of NUP62-depleted
nuclear pores, rather than by the loss of an autonomous
function of NUP62. For counting, viable cells were distin-
guished by exclusion of trypan blue. As previously shown,
knockdown of NUP160 greatly reduces the density of pores
in the nuclear envelope; however, it does not reduce the
sensitivity of cells to cisplatin, with TOV112D-9 cells treated
with NUP160 siRNA displaying a dose-response to cisplatin
after 48 hours similar to cells treated with control siRNA
(Figure 5B). Knockdown of both NUP160 and NUP62 ab-
rogated the ability of NUP62 knockdown alone to promote
survival of cells in cisplatin (Figure 5B), suggesting that
accumulation of NUP62-depleted nuclear pores is required
to confer drug resistance.
We queried whether selection of cultured cells with
cisplatin results in accumulation of cells expressing less
NUP62. Cells that recovered after selection with 4 g/mL
of cisplatin for 48 hours displayed detectable resistanceto cisplatin (measured as viability after 72 hours in differ-
ent concentrations of cisplatin; Figure 6A). The cultures
were harvested or assayed immediately on growing back
to 80% confluence, and a modest reduction in total
NUP62 was detected by using Western blot analysis of
the cultures after one or two cycles of selection (Figure
6B). We also queried whether knockdown of NUP62 con-
fers extended resistance to cisplatin independently of
exposure to the drug. Cells were treated with NUP62 or
control siRNA for 72 hours, siRNA was removed from the
medium, the cells were cultured for nine generations
(three passes of 1:8), and then the cells were tested for
sensitivity to cisplatin. Surprisingly, in the absence of
prior exposure to cisplatin and after sufficient culture time
to dilute parent (siRNA-treated) cells to at least 1:512, a
modest, but statistically significant, level of cisplatin re-
sistance was detected (Figure 6C). Western blot analy-
ses did not reveal an obvious difference in total NUP62
accumulation between control and NUP62 siRNA-treated
cultures after nine generations, although it is possible that
moderate changes in a fraction of the cells or changes
restricted to a short phase of the cell cycle would escape
Figure 5. Knockdown of NUP62 confers cisplatin resistance in TOV112D
cells. A: Phase microscopy of TOV112D-9 cells treated with either control or
NUP62 siRNA for 24 hours, then treated with the indicated concentration of
cisplatin for 48 hours. Scale bar 100 m. B: Cells were treated with control,
NUP62, NUP160, or a combination of NUP62 and NUP160 siRNAs for 24
hours, then cisplatin was added, and cell counts were taken 48 hours after
adding cisplatin. Different quantities of NUP62 and NUP160 siRNA were
added to 600-L cultures (indicated in pmol). The SEs are shown for multiple
wells in a single experiment; all experimental determinations were per-
formed independently several times, with consistent results.detection by this gross method.
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Dormancy by Modulation of NUP62 Expression
As previously indicated, knockdown of NUP62 results in
growth arrest that is reversible on removal of NUP62
siRNA, whereas knockdown of NUP62 and treatment with
cisplatin result in enhancement of survival, accompanied
by entry of cells into protracted growth arrest (dormancy).
We sought to determine whether induction of NUP62
expression awakened the latter cells from dormancy. The
TOV112D-9 (containing only pTet-on) and TOV112D-
CAP (containing both pTet-on and TRE-NUP62) cell
lines cultured in tetracycline-free medium were treated
on day 1 with NUP62 or control siRNA for 24 hours;
then, 4.5 g/mL cisplatin was added to some cultures
for 72 hours (Cis, day 5; Figure 7, A and B). Cisplatin
and siRNAs were removed, and the cells were cultured in
nominal medium for 7 days (Cis, day 12; Figure 7, A
and B). Doxycycline was added to some cultures for 5
days and then removed, and the cultures were main-
tained in nominal medium for 7 additional days (Cis,
Dox, day 24; Figure 7B). For the TOV112D-9 cells, the
cultures were also maintained for a further 6 weeks, with
changes of nominal medium every 4 days (Cis, Dox,
day 66; Figure 7B). As shown in Figure 7B, TOV112D-9
cells at day 24 displayed no colonies. Rarely, a few
colonies will appear in the TOV112D-9 cultures treated
with NUP62 siRNA and cisplatin after being maintained
for 6 weeks, such as the two small colonies appearing
at day 66 (Figure 7B). In contrast, TOV112D-CAP cells
treated with NUP62 siRNA and cisplatin displayed abun-
dant colonial growth soon after transient treatment with
doxycycline (Cis, Dox, day 24; Figure 7B), but only a
few large colonies were present in parallel cultures that
were not treated with doxycycline (Cis, -Dox, day 24;
Figure 7B). In TOV112D-CAP cultures that were treated with
NUP62 siRNA and cisplatin, two types of colonies could be
distinguished at day 24 after treatment with doxycycline:
sparse large colonies and abundant small colonies. In sim-
ilarly treated TOV112D-CAP cultures lacking doxycycline,
only sparse large colonies were observed at day 24.We interpret the data from the colony assays as
follows: TOV112D-9 cultures lack the doxycycline-in-
ducible NUP62 expression construct, and, thus, only
express NUP62 from the endogenous gene. On knock-
Figure 6. Cisplatin-selected TOV112D cells dis-
play modest reduction of NUP62; cells treated with
NUP62 siRNA retain some cisplatin resistance after
several generations. A: TOV112D-9 cells were se-
lected by two rounds of treatment with 4 g/mL
cisplatin for 48 hours and recovery, and analyzed
for relative viability after treatment with different
concentrations of cisplatin for 72 hours. Cells from
the first passage after recovery were analyzed. B:
Top panel: Western blot analysis of TOV112D-9
cells after one or two rounds of treatment and
recovery from 4 g/mL cisplatin for 48 hours. Bot-
tom panel: Relative band densities normalized to
GAPDH. Cells from the first passage after recovery
were analyzed. C: Pretreatment of TOV112D
TOV112D-CAP (bottom) cells with NUP62 siRNA
for 72 hours confers resistance to cisplatin that is
partly retained over several generations. Top and
bottom: Independent experiments. After treat-
ment with NUP62 siRNA, the cells were cultured
for three passes of 1:8, then tested for sensitivity to
different concentrations of cisplatin treatment for
48 hours. The results are shown with paired t-test
P values.
Figure 7. Entry or exit of TOV112D cells from drug-resistant dormancy can
be induced by modulation of NUP62 expression. TOV112D-9 or TOV112-
CAP cells were grown to 80% confluence (day 0), treated with control or
NUP62 siRNA for 24 hours (day 1), then cultured for 3 days in the absence
(-Cis) or presence (Cis) of cisplatin (day 5). Cisplatin and siRNAs were
removed on day 5, and the cells were cultured for 7 days (day 12). Doxy-
cycline was added to some of the cultures for 5 days (Dox), then removed,
and the cultures were maintained for 7 more days (day 24). The TOV112D
cells were also maintained for 6 weeks longer in the absence of cisplatin and
siRNAs (day 66). A: Phase-contrast microscopy of cultures at days 5 and 12.
Scale bar  100 m. B: Cultures were fixed and stained with crystal violet.
Reverse black-and-white images are shown for clarity.
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cisplatin, the resistant TOV112D-9 cells enter dor-
mancy, interrupted in long-term cultures only by the
rare stochastic conversion to growth of single cells,
leading to the formation of a colony. After knockdown
of NUP62, treatment with cisplatin, and removal of cis-
platin, TOV112D-CAP cells also enter dormancy but
are pushed back into the cell cycle when expression of
NUP62 is induced by transient treatment with doxycy-
cline. This is apparent from an abundance of small
colonies that appear after treatment of TOV112D-CAP
cultures with doxycycline. The sparse large colonies
that appear in TOV112D-CAP but not TOV112D-9 cul-
tures have a related ontogeny. Although the tetracy-
cline transactivator protein is engineered to bind and
activate the TRE when associated with doxycycline, a
low level of binding is present in the absence of doxy-
cycline, and incrementally higher levels of NUP62 ex-
pression probably arise in some cells. After removal of
cisplatin, the emergence of these cells precedes that
of the TOV112D-CAP cells that are stimulated to growth
by doxycycline and results in the generation of a few
large colonies in both cultures with and without doxy-
cycline.Variation of NUP62 Accumulation and
Distribution in Ovarian Carcinomas
To begin to explore whether modulation of NUP62 accu-
mulation and NPC architecture occur during tumor
growth in vivo, tissue homogenates from primary and met-
astatic high-grade ovarian carcinomas (fresh resected
tumors) were analyzed by using Western blot analysis for
NUP62 accumulation. A comparison of the relative inten-
sities of the NUP62 bands indicated that many ovarian
carcinomas accumulate less total NUP62 than normal
ovarian tissue (derived from epithelial cell–dense gyri on
the surface of the ovary; Figure 8A). Furthermore, the
nuclear pore structure of normal ovarian epithelial and
ovarian serous carcinoma cells was observed by trans-
mission electron microscopy. Embedded in the central
channel of the nuclear pore of normal ovarian epithelial
cells is an electron-dense bar of material that represents
the two inner ring structures containing the NUP62 com-
plex. The central channel of nuclear pores in ovarian
epithelial tumor cells frequently lacked this electron-
dense bar, as did nuclear pores from cultured tumor cells
Figure 8. Alterations in NUP62 accumulation
and distribution in high-grade ovarian carcino-
mas. A: From whole tissue, homogenates of
fresh resected primary and metastatic high-grade
serous ovarian carcinomas were analyzed using
Western blot analysis for NUP62 accumulation
(equal total protein per lane). Normal ovarian
tissue was derived from epithelial cell–dense
gyri on the surface of the ovary. B: Transmission
electron microscopy of an NPC in normal ovar-
ian epithelium [which contains a dense inner
ring (arrow)], in high-grade serous ovarian car-
cinoma, and in TOV112D cells treated with
NUP62 siRNA. Cytoplasmic (Cyt.) and nuclear
(Nu.) compartments are indicated. C: Measure-
ment and comparison of inner pore diameters of
NPCs from four high-grade serous ovarian carci-
nomas with four normal ovarian epithelium sam-
ples. D: IHC stains of paraffin-embedded, high-
grade ovarian serous carcinoma sections
distinguished two patterns of staining that ap-
peared in various proportions among cells in
each tumor. Left panel: Red, a tumor with a
high portion of uniform staining across the entire
nucleus. Center panel: Green, a tumor with a
high portion of defined perimetrical staining
around the nucleus, with little staining in the
central region. Right panel: Samples were
scored and counted for perimetrical and uniform
NUP62 nuclear staining; tumors displaying a
greater fraction of perimetrical stained tumor nu-
clei (green type) were distinguished from those
displaying a greater fraction of uniform nuclear
staining (red type). A Kaplan-Meier analysis of
the progression-free interval for these two pop-
ulations is shown.treated with NUP62 siRNA (Figure 8B). The absence of
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a dilated appearance, as was quantified by comparison
of the inner pore diameters from four ovarian carcinomas
(high-grade serous) with those from the ovarian surface
epithelia of four healthy controls (Figure 8C). Interest-
ingly, the frequent appearance of dilated nuclear pores in
ovarian carcinoma cells is similar to the appearance of
nuclear pores in picornavirus infected cells, consistent
with the observation that picornavirus infection also re-
sults in down-regulation of NUP62.58
Because NUP62 is distributed between NPC and in-
tranuclear and cytoplasmic pools, distribution of NUP62
among these pools and among NPC populations may
relate to tumor phenotype. Although differences in total
accumulation of NUP62 may affect drug resistance
and/or dormancy, redistribution of NUP62 between nu-
clear and cytoplasmic pools, or between NPC popula-
tions, may be functionally equivalent. Although immuno-
histochemical (IHC) studies have limited resolution at the
subcellular level, it is nonetheless possible to distinguish
grossly different nuclear and cytoplasmic distributions of
NUP62. By using IHC stains of paraffin-embedded tissue
sections, we distinguished two general distributions of
NUP62 in the nuclei of high-grade ovarian carcinomas: a
relatively uniform dense staining across the entire nu-
cleus and a discrete perimetrical ring of staining on the
nuclear envelope, with little staining in the central regions
(Figure 8D). One interpretation of these staining patterns
is that the tight perimetrical pattern represents an atten-
uated NUP62 distribution that is restricted to a dense ring
of NPCs on the nuclear envelope, whereas the uniform
pattern represents cells with more abundant NUP62 dis-
tributed among NPCs at additional sites on the entire
nuclear envelope, and possibly in intranuclear sites as
well. We evaluated the utility of these two NPC patterns
with a training group of pathological specimens from
patients with stage III ovarian carcinomas subsequently
given primary platinum therapy and observed. The sam-
ples were scored and counted for perimetrical and uniform
NUP62 nuclear staining. Tumors displaying a greater frac-
tion of perimetrical stained tumor nuclei were distinguished
from those displaying greater uniform nuclear staining. As
shown in Figure 8D, Kaplan-Meier analysis of the progres-
sion-free interval indicated that increased frequency of per-
imetrical rim NUP62 staining nuclei in a tumor may predict a
poor response to platinum chemotherapy (log-rank P value,
0.018; Wilcoxon P value, 0.016).
Discussion
Inhibition of G1 or G2 phase cell cycle progression by
most cytostatic agents has enhanced, rather than re-
duced, the cytotoxicity of cisplatin.42–48 Thus, although
knockdown of NUP62 results in cell cycle arrest, protec-
tion against cisplatin cannot result merely from restricting
progression of cells into or through the S phase. Rather,
cisplatin resistance after knockdown of NUP62 may be
conferred by protective or anti-apoptotic mechanisms
that are restricted to the specific stage of the G1 phase of
the cell cycle, in which the cells are paused. By compar-ison with cell cycle arrest in aphidicolin-treated cells, we
showed that knockdown of NUP62 results in a pause in
cell cycle progression at a point upstream from the G1-S
border. Interestingly, cells that pass this point appear
competent to complete the remainder of the cell cycle,
even in the continuing presence of NUP62 siRNA, sug-
gesting that NUP62 knockdown blocks progression ex-
clusively through this stage of the G1 phase. Western blot
analyses revealed that total NUP62 accumulation dis-
plays a peak early in the G1 phase, before the peak of
cyclin E accumulation. Together, the data suggest that
enhanced accumulation of NUP62 may be required for
passage through an early stage of the G1 phase. The
relationship of this G1 phase restriction point to other
restriction points in the G1 phase, including those di-
rected by phosphatidylinositol 3-kinase, contact inhibi-
tion or growth factor depletion, and/or differentiation,59
remains to be investigated. Whether a specific restriction
point exists in the early G1 phase that can only be passed
if a critical number or fraction of NUP62 NPCs has been
achieved remains to be further elucidated. In contrast to
knockdown, overexpression of NUP62 resulted in apop-
tosis, depleting cells from the G1 phase in asynchronous
cultures. This observation suggests that both up- and
down-regulation of NUP62 during the G1 phase may be
required for successful transit of cells to the S phase.
Although the observed pause in the G1 phase after
NUP62 knockdown may be functionally related to entry of
TOV112D-9 and TOV112D-CAP cells into dormancy, cis-
platin resistance could be conferred by cell cycle–inde-
pendent effects of increasing the abundance of NUP62-
depleted NPCs. The NUP62 content of NPCs could
influence sensitivity to cisplatin through several possible
mechanisms; however, reduction of nucleocytoplasmic
transport mediated by NUP62 does not appear to be one
of them. Knockdown of NUP160, which dismantles the
NPC, or of both NUP62 and NUP160 did not detectably
reduce TOV112D-9 cell sensitivity to the cytotoxic effect
of cisplatin, suggesting that mere disruption of nucleocy-
toplasmic transport does not confer resistance. Rather,
the enrichment of NUP62-depleted NPC complexes ap-
pears to confer cisplatin resistance through an active
mechanism. In addition to nucleocytoplasmic transport,
the NPC functions in the organization of underlying chro-
matin, and NUPs appear to function in transcriptional
regulation and in the intranuclear movement of certain
genes from transcriptionally silent, heterochromatic pe-
ripheral regions of the nucleus to transcriptionally active,
euchromatic central regions.36,37,60,61 The enrichment of
NUP62-depleted NPC complexes may directly affect the
organization of underlying chromatin and, thereby, re-
duce sensitivity to cisplatin by altering gene expression
or by other potential mechanisms, including limiting ac-
cess of the drug to certain regions of DNA.
Treatment of TOV112D-9 cells with NUP62 siRNA re-
sults in growth retardation, but normal growth resumes
within a few days after removal of siRNA. In contrast,
treatment with NUP62 siRNA and cisplatin resulted in the
surviving cells entering a state of growth arrest that was
refractory to removal of NUP62 siRNA and cisplatin. It is
possible that treatment with NUP62 siRNA alone pro-
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growth arrest and a smaller population that has entered
dormancy, with the latter population resistant to cisplatin.
Thus, in the absence of cisplatin selection, removal of
NUP62 siRNA would permit regrowth of the population in
transient growth arrest over the dormant population. After
cisplatin selection, only the dormant population would
remain, and this population would not grow back spon-
taneously after removal of NUP62 siRNA. The delay in
recovery of proliferating cultures after removal of NUP62
siRNA is consistent with this model, although that delay
may be merely the time required for de novo expression
and translation of NUP62. Also, cultures treated with
NUP62 siRNA in the absence of cisplatin retain some
cisplatin resistance after several generations, supporting
the view that resistant cells have the capacity to prolifer-
ate after the removal of NUP62 siRNA. The retention of
cisplatin resistance several cell generations after the re-
moval of NUP62 siRNA also suggests that knockdown of
NUP62 confers changes to chromatin organization that
are somehow retained during proliferation. Such changes
may represent a novel pathway for epigenetic regulation.
At least three major mechanisms have been associ-
ated with tumor dormancy: generation of tumor vascula-
ture (angiogenesis), evasion of immune responses, and
entry/exit of tumor cells from the cell cycle (sometimes
distinguished as cellular dormancy49,62). Tumor dor-
mancy can follow therapeutic intervention, but it is also
exhibited by primary tumors, because their growth can
lag or stall before they become clinically significant.63–65
Protracted tumor dormancy can occur after treatment;
tumor cells that resist therapy can persist in an occult or
asymptomatic state for years before causing a recur-
rence of disease.66 The mechanisms of cancer cell rele-
gation to cellular dormancy, whether preceded by thera-
peutic intervention or during progression to an oncogenic
state, are not well understood. The mechanisms that in-
duce dormant cancer cells to awaken and proliferate are
equally elusive. The culture system presented herein of-
fers a controlled platform from which to study entry of
tumor cells into protracted quiescence after treatment
with a therapeutic agent, as well as a rapid mechanism
for awakening dormant cells and inducing proliferation.
Some evidence is presented herein that intrinsic modu-
lation of NUP62 may be a direct mechanism through
which ovarian carcinomas resist therapeutics and/or en-
ter or exit from cellular dormancy. It is not clear the
synthetic level at which accumulation of NUP62 is regu-
lated, and whether changes in NPC architecture arise
exclusively from changes in NUP62 accumulation or from
other mechanisms, such as subcellular redistribution.
Changes in NPC architecture and/or the associated
changes in chromatin organization may be effectors of
drug resistance or dormancy; they also may lie down-
stream from other signaling pathways or regulators. Mod-
ulation of NUP62 represents a method to produce rela-
tively uniform populations of cells either entering or
exiting protracted dormancy and drug resistance, and
gene expression profiling and bioinformatic techniques
can be applied to this system to yield further insights intothe signaling and effector systems that affect these pro-
cesses.
The defective state of p53 in TOV112D cells indi-
cates that induction of drug resistance and/or dor-
mancy by NUP62 knockdown does not require p53.
Many studies67–69 have demonstrated a central role for
p53 in directing tumor cells toward premature senes-
cence, and recently, removal of senescent tumor cells by
the immune system has been identified as a mechanism
of tumor clearance.70 Senescence and tumor cell dor-
mancy, although both quiescent states (albeit one termi-
nal and the other not), may differ by a stronger relation-
ship between dormant cells and cancer stem cells, the
pool of cells involved in tumor renewal. Although loss of
p53 function may be a key mechanism through which
epithelial tumor cells escape senescence, and p53 ac-
tivity may maintain angiogenesis-restricted dorman-
cy,71–73 a connection between p53 activity and entry or
exit from cellular dormancy has not been established. In
fact, recent studies74 have suggested an oppositional
relationship between p53 activity and expansion of the
stem cell phenotype. In the experiments presented
herein, the TOV112D cells are derived from a high-grade
ovarian epithelial carcinoma with endometrioid histologi-
cal features, and they express defective p53.38 An inter-
esting query for future studies will be how the effects of
NUP62 knockdown on drug resistance and dormancy
compare in tumor cell lines with normal or defective p53.
The pro-apoptotic effect of NUP62 overexpression
may be reminiscent of p53: activation of p53 restricts cell
cycle progression at both the late G1 phase and G2-M,
75
whereas NUP62 knockdown restricts progression only
through a part of the G1 phase. Alterations in the p53
gene have been associated with variable responses to
cisplatin in cultured cell lines, including some lines de-
rived from ovarian tumors.10,76 Further study has shown
that, although p53 activation may contribute to the cyto-
toxic response to cisplatin of normal cells, such as kidney
epithelium,77,78 the role of p53 status in the relative re-
sponses of ovarian epithelial tumors is not as clear.79,80
Because tumor cells with defective p53 can display sen-
sitivity to cisplatin, it is apparent that the response to
cisplatin in tumor cells may use alternate pathways.81–83
Equally important, p53 defects are prevalent in high-
grade ovarian epithelial tumors and in some other epithe-
lial tumor types, suggesting that these mutations occur
early during the tumorigenic progression of these cancer
cell lineages.18,19 Prognostic breakdown of high-grade
cancers using gene expression profiling approaches,
however, has proved challenging.84,85 The results pre-
sented herein suggest that a better understanding of the
three-dimensional structure of the nucleus, in particular
the spatial arrangement and architecture of the NPCs
and the underlying effects on chromatin organization,
could provide insights into predicting how different high-
grade ovarian carcinomas will respond to therapeutic
intervention.
Epigenetic regulatory mechanisms can work in concert
with somatic mutations to drive tumor progression and
promote tumor cell survival. For example, in a subset of
ovarian carcinomas (perhaps as high as 20%), methyl-
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thereby promoting other neoplastic changes.86 Subse-
quent reversion of these genes to demethylated forms
restores drug tolerance to this subset of cancers. The
epigenetic machinery of the cell includes DNA methyl-
ation, histone modifications, noncoding RNAs, and chro-
matin remodeling and organization, the latter being af-
fected by the first three and by the architecture of the
nucleus. In addition, contingent on gene and tissue
type,61,87 metazoan genes localized adjacent to the nu-
clear envelope generally tend to be suppressed,
whereas genes localized centrally in the nucleoplasm
tend to be transcriptionally active.60,88 Chromatin orga-
nization appears to be influenced by its proximity to the
NPC, because channels of euchromatin interrupt the lam-
ina and extend from the NPC into the nucleus.89 Although
associations between specific NPCs and specific gene
groups have not yet been reported in metazoans, stud-
ies90,91 in Drosophila and human fibroblasts have
shown that chromosomal organization in the interphase
nucleus is directed by specific associations between
chromatin and the nuclear lamina. Future studies could
be aimed at how changes in NPC architecture affect
chromatin organization directly or indirectly through inter-
actions with the nuclear lamina. The outcome of such
studies may better define how changes in NUP abun-
dance or in NPC architecture influence gene expression
and how such mechanisms contribute to the phenotypic
diversity and adaptive responses of cancer cells.
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